Objective: The clinical outcome of intracranial infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB) remains unsatisfactory, even when treated with combined antibiotic therapy. This study successfully cured 1 patient with XDRAB intracranial infection after cranial surgery through a multichannel combination of drugs, providing a reference for the clinical treatment of severe XDRAB intracranial infection.
Methods: The clinical data of a patient with an XDRAB intracranial infection after a craniocerebral operation were retrospectively analyzed, and the treatment approach for XDRAB intracranial infection was examined.
Results: Upon the occurrence of XDRAB intracranial infection after craniocerebral surgery, the patient was given an intravenous injection of polymyxin B+ tigecycline + amikacin, while intrathecal injection of polymyxin B, and the intracranial infection was controlled and cured.
Conclusions: Polymyxin B+ tigecycline + amikacin intravenous and intrathecal polymyxin B can benefit XDRAB intracranial infected patients after craniofacial surgery.
Copyright © 2024 by Mutaz B. Habal, MD.